Document is current
Any future updates will be listed below
-
Authors
Morlock, Robert J.
Dalal, Deepan
Divino, Victoria
DeKoven, Mitchell
Taylor, Stephanie D.
Powers, Atsuko
Barretto, Naina
Holt, Robert J.
LaMoreaux, Brian https://orcid.org/0000-0001-7521-241X
-
Funding
Funding for this research was provided by:
Horizon Therapeutics
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 22 October 2024
First Online: 14 November 2024
Declarations
:
: Robert J. Morlock was a consultant for Horizon Therapeutics (now Amgen Inc); Deepan Dalal has no conflicts to report; Victoria Divino and Mitchell DeKoven are employees of IQVIA, which received funding for this study from Horizon Therapeutics (now Amgen Inc); Brian LaMoreaux, Stephanie Taylor, Atsuko Powers, Naina Baretto, and Robert J. Holt were employees and shareholders of Horizon Therapeutics (now Amgen Inc) at the time the study was conducted. Brian LaMoreaux, Atsuko Powers, and Naina Baretto are current employees and shareholders of Amgen Inc.
: The study used the IQVIA PharMetrics® Plus database, a longitudinal commercial health-plan database of adjudicated integrated medical and pharmacy claims. Because this study was conducted using only de-identified data collected in compliance with Health Insurance Portability and Accountability Act of 1996 regulations and the act’s Omnibus Rule of 2013, informed consent was not necessary, and IRB approval was not sought. The study was conducted according to the Declaration of Helsinki.
